Lawrence F Kuklinski1, Shufeng Li2, Margaret R Karagas3, Wen-Kai Weng4, Bernice Y Kwong5. 1. Department of Pathology, Stanford University School of Medicine, Stanford, California. 2. Department of Dermatology, Stanford University School of Medicine, Stanford, California. 3. Department of Epidemiology, Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire. 4. Department of Dermatology, Stanford University School of Medicine, Stanford, California; Department of Medicine, Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, California. Electronic address: wkweng@stanford.edu. 5. Department of Dermatology, Stanford University School of Medicine, Stanford, California. Electronic address: bernicek@stanford.edu.
Abstract
BACKGROUND: Voriconazole has previously been associated with increased risk for cutaneous squamous cell carcinoma (SCC) in solid organ transplant recipients. Less is known about the risk in patients after hematopoietic cell transplantation (HCT). OBJECTIVE: We evaluated the effect of voriconazole on the risk for nonmelanoma skin cancer (NMSC), including SCC and basal cell carcionoma, among those who have undergone allogeneic and autologous HCT. METHODS: In all, 1220 individuals who had undergone allogeneic HCT and 1418 who had undergone autologous HCT were included in a retrospective cohort study. Multivariate analysis included voriconazole exposure and other known risk factors for NMSC. RESULTS: In multivariate analysis, voriconazole use increased the risk for NMSC (hazard ratio, 1.82; 95% confidence interval, 1.13-2.91) among those who had undergone allogeneic HCT, particularly for SCC (hazard ratio, 2.25; 95% confidence interval, 1.30-3.89). Voriconazole use did not appear to confer increased risk for NMSC among those who had undergone autologous HCT. LIMITATIONS: This is a retrospective study. CONCLUSION: Voriconazole use represents an independent factor that may contribute to increased risk specifically for SCC in the allogeneic HCT population.
BACKGROUND:Voriconazole has previously been associated with increased risk for cutaneous squamous cell carcinoma (SCC) in solid organ transplant recipients. Less is known about the risk in patients after hematopoietic cell transplantation (HCT). OBJECTIVE: We evaluated the effect of voriconazole on the risk for nonmelanoma skin cancer (NMSC), including SCC and basal cell carcionoma, among those who have undergone allogeneic and autologous HCT. METHODS: In all, 1220 individuals who had undergone allogeneic HCT and 1418 who had undergone autologous HCT were included in a retrospective cohort study. Multivariate analysis included voriconazole exposure and other known risk factors for NMSC. RESULTS: In multivariate analysis, voriconazole use increased the risk for NMSC (hazard ratio, 1.82; 95% confidence interval, 1.13-2.91) among those who had undergone allogeneic HCT, particularly for SCC (hazard ratio, 2.25; 95% confidence interval, 1.30-3.89). Voriconazole use did not appear to confer increased risk for NMSC among those who had undergone autologous HCT. LIMITATIONS: This is a retrospective study. CONCLUSION:Voriconazole use represents an independent factor that may contribute to increased risk specifically for SCC in the allogeneic HCT population.
Authors: Y Inamoto; N N Shah; B N Savani; B E Shaw; A A Abraham; I A Ahmed; G Akpek; Y Atsuta; K S Baker; G W Basak; M Bitan; Z DeFilipp; T K Gregory; H T Greinix; M Hamadani; B K Hamilton; R J Hayashi; D A Jacobsohn; R T Kamble; K A Kasow; N Khera; H M Lazarus; A K Malone; M T Lupo-Stanghellini; S P Margossian; L S Muffly; M Norkin; M Ramanathan; N Salooja; H Schoemans; J R Wingard; B Wirk; W A Wood; A Yong; C N Duncan; M E D Flowers; N S Majhail Journal: Bone Marrow Transplant Date: 2015-03-30 Impact factor: 5.483
Authors: Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard Journal: Clin Infect Dis Date: 2011-02-15 Impact factor: 9.079
Authors: John R Wingard; Navneet S Majhail; Ruta Brazauskas; Zhiwei Wang; Kathleen A Sobocinski; David Jacobsohn; Mohamed L Sorror; Mary M Horowitz; Brian Bolwell; J Douglas Rizzo; Gérard Socié Journal: J Clin Oncol Date: 2011-04-04 Impact factor: 44.544
Authors: W Hasegawa; G R Pond; J T Rifkind; H A Messner; A Lau; A S Daly; T L Kiss; N Kotchetkova; A Galal; J H Lipton Journal: Bone Marrow Transplant Date: 2005-01 Impact factor: 5.483
Authors: T Martin; M Sharma; L Damon; L Kaplan; B J Guglielmo; M Working; R O'Malley; J Hwang; C Linker Journal: Transpl Infect Dis Date: 2009-09-30 Impact factor: 2.228
Authors: Sarah N Robinson; Michael S Zens; Ann E Perry; Steven K Spencer; Eric J Duell; Margaret R Karagas Journal: J Invest Dermatol Date: 2013-01-23 Impact factor: 8.551
Authors: Jennifer T Huang; Carrie C Coughlin; Elena B Hawryluk; Kristen Hook; Stephen R Humphrey; Lacey Kruse; Leslie Lawley; Hasan Al-Sayegh; Wendy B London; Ashfaq Marghoob; Thuy L Phung; Elena Pope; Pedram Gerami; Birgitta Schmidt; Sarah Robinson; Diana Bartenstein; Eman Bahrani; Meera Brahmbhatt; Lily Chen; Ellen Haddock; Danny Mansour; Julie Nguyen; Tom Raisanen; Gary Tran; Kate Travis; Zachary Wolner; Lawrence F Eichenfield Journal: J Pediatr Date: 2019-05-15 Impact factor: 4.406
Authors: Edward B Li; Johanna S Song; Jennifer T Huang; Elena B Hawryluk; Wendy B London; Dongjing Guo; Madhumitha Sridharan; David E Fisher; Corinna J Rea; Leslie E Lehmann; Christine N Duncan Journal: Pediatr Dermatol Date: 2019-08-13 Impact factor: 1.588
Authors: Jeffrey F Scott; Kevin R Brough; Konstantin V Grigoryan; John G Muzic; Grace Y Kim; Rosalynn R Z Conic; Sheena T Hill; Jerry D Brewer; Christian L Baum; Mark R Litzow; William J Hogan; Mrinal S Patnaik; Shahrukh K Hashmi; Hillard M Lazarus; Jeremy S Bordeaux; Cheryl L Thompson; Meg R Gerstenblith; Julia S Lehman Journal: JAMA Dermatol Date: 2020-06-01 Impact factor: 10.282
Authors: Jennifer Berano Teh; Farah Abdulla; Kelly Peng; Liezl Atencio; Meagan Echevarria; Aleksi Iukuridze; Alan C Geller; F Lennie Wong; Stephen J Forman; Ryotaro Nakamura; Badri Modi; Saro H Armenian Journal: J Invest Dermatol Date: 2021-02-18 Impact factor: 7.590
Authors: Saro H Armenian; Lanie Lindenfeld; Aleksi Iukuridze; Meagan Echevarria; Samantha Bebel; Catherine Coleman; Ryotaro Nakamura; Farah Abdullah; Badri Modi; Kevin C Oeffinger; Karen M Emmons; Ashfaq A Marghoob; Alan C Geller Journal: BMC Cancer Date: 2020-08-03 Impact factor: 4.430